Efficacy of chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia.
- Author:
Cheng FANG
1
;
Wei XU
;
Min XU
;
Ming HONG
;
Dan-xia ZHU
;
Hua-yuan ZHU
;
Yu-jie WU
;
Lei FAN
;
Chun QIAO
;
Yun ZHUANG
;
Kou-rong MIAO
;
Peng LIU
;
Jian-yong LI
Author Information
- Publication Type:Clinical Trial
- MeSH: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; administration & dosage; Antineoplastic Combined Chemotherapy Protocols; therapeutic use; Cyclophosphamide; administration & dosage; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; drug therapy; Male; Middle Aged; Rituximab; Treatment Outcome; Vidarabine; administration & dosage; analogs & derivatives
- From: Chinese Journal of Hematology 2011;32(1):3-7
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy of combination chemoimmunotherapy of fludarabine, cyclophosphamide and rituximab (FCR) in chronic lymphocytic leukemia (CLL).
METHODSTwenty-one patients with CLL were treated with FCR regimen which consisted of fludarabine (25 mg/m(2), days 2 to 4), cyclophosphamide (250 mg/m(2), days 2 to 4) and rituximab (375 mg/m(2), day 1) in a course of 28 days. The minimal residual disease (MRD) was determined by multiparameter flow cytometry. The correlation between the pretreatment characteristics and complete remission (CR) rate was analyzed.
RESULTSEleven patients (52.4%) achieved CR, 7 (33.3%) achieved partial remission (PR) with a overall response (OR) rate of 85.7%. With a median follow-up time of 19 (7 - 73) months, the overall survival (OS) was 86.0%, and the progression-free survival (PFS) was 72.0%. Pretreatment parameters independently associated with higher CR rates were Binet stage A + B, IgVH mutated and ZAP-70 less than 20%. MRD was less than 1% in 6 patients. The most common toxicities were myelosuppression and gastrointestinal reaction.
CONCLUSIONFCR is an effective regimen for CLL patients.
